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IMPORTANCE Creutzfeldt-Jakob disease (CJD) and autoimmune encephalitis with antibodies
against neuronal surface antigens (NSA-abs) may present with similar clinical features.
Establishing the correct diagnosis has practical implications in themanagement of care for
these patients.
OBJECTIVE To determine the frequency of NSA-abs in the cerebrospinal fluid of patients with
suspected CJD and in patients with pathologically confirmed (ie, definite) CJD.
DESIGN, SETTING, AND PARTICIPANTS Amixed prospective (suspected) and retrospective
(definite) CJD cohort study was conducted in a reference center for detection of NSA-abs.
The population included 346 patients with suspected CJD and 49 patients with definite CJD.
MAIN OUTCOMES ANDMEASURES Analysis of NSA-abs in cerebrospinal fluid with brain
immunohistochemistry optimized for cell-surface antigens was performed. Positive cases in
the suspected CJD group were further studied for antigen specificity using cell-based assays.
All definite CJD cases were comprehensively tested for NSA-abs, with cell-based assays used
for leucine-rich glioma-inactivated 1 (LGI1), contactin-associated protein-like 2 (CASPR2),
N-methyl-D-aspartate (NMDA), and glycine (GlY) receptors.
RESULTS Neuronal surface antigens were detected in 6 of 346 patients (1.7%) with rapid
neurologic deterioration suggestive of CJD. None of these 6 patients fulfilled the diagnostic
criteria for probable or possible CJD. The target antigens included CASPR2, LGI1, NMDAR,
aquaporin 4, Tr (DNER [δ/notch-like epidermal growth factor–related receptor]), and an
unknown protein. Four of the patients developed rapidly progressive dementia, and the other
2 patients had cerebellar ataxia or seizures that were initially considered to bemyoclonus
without cognitive decline. The patient with Tr-abs had a positive 14-3-3 test result. Small cell
lung carcinomawas diagnosed in the patient with antibodies against an unknown antigen. All
patients improved or stabilized after appropriate treatment. None of the 49 patients with
definite CJD had NSA-abs.
CONCLUSIONS AND RELEVANCE A low, but clinically relevant, number of patients with
suspected CJD had potentially treatable disorders associated with NSA-abs. In contrast, none
of 49 patients with definite CJD had NSA-abs, including NMDAR-abs, GlyR-abs, LGI1-abs, or
CASPR2-abs. These findings suggest that cerebrospinal fluid NSA-abs analysis should be
included in the diagnostic workup of patients with rapidly progressive central nervous system
syndromes, particularly when they do not fulfill the diagnostic criteria of probable or possible
CJD.
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C reutzfeldt-Jakobdisease (CJD) andcentral nervous sys-tem (CNS)disorders associatedwith antibodies againstneuronal surface antigens (NSA-abs)maypresentwith
similar clinical features. Unlike CJD, CNS disorders associ-
ated with NSA-abs are potentially treatable and often have a
good outcome if diagnosed and treated early.1 The diagnosis
of these immune-mediateddisorders is basedon the rapidpre-
sentation of symptoms and detection of antibodies in serum
and cerebrospinal fluid (CSF); other tests, such as electroen-
cephalography or magnetic resonance imaging, are less use-
ful because they may show nonspecific findings, and mag-
netic resonance imaging is normal in 10% to 60% of patients
depending on the antibody type.2 Creutzfeldt-Jakob disease
usuallypresentswith rapidlyprogressive cognitiveand/ormo-
tor symptoms, and the diagnosis is supported by the pres-
ence of characteristic electroencephalographic andmagnetic
resonance imaging findings aswell as increased levels of neu-
ronal injury markers in the CSF, particularly the 14-3-3 pro-
tein. The diagnostic accuracy of each test varies and depends
on the phase of the disease and the genotype on codon 129.3
The 14-3-3 test is negative in approximately 12%to 14%ofdefi-
nite sporadicCJD,4-6 and false-positive resultshavebeen found
in several neurologic diseases characterized by acute and ex-
tensive neuronal damage, including paraneoplastic neuro-
logic disorders.7,8 On the other hand, recent studies suggest
that antibodies to the N-methyl-D-aspartate receptor
(NMDAR-abs),9,10 glycine receptor (GlyR-abs),11 and voltage-
gated potassium channel (VGKC-abs) complex12may occur in
the serum of patients with CJD, further complicating the dif-
ferential diagnosis of these disorders. The aim of the present
studywas to systematically determine the frequency of NSA-
abs in 346 suspected and 49 pathologically confirmed cases




Our laboratory is a reference center for 14-3-3 andneuronal an-
tibody testing in Spain and has collaborated in the CJD sur-
veillancesysteminCatalonia, Spain, forCJDcasedetectionand
diagnosis since 1997. We receive approximately 400 CSF
samples per year obtained from patients with suspected CJD
for 14-3-3 protein determination. During 2012, we prospec-
tively tested all CSF samples received for 14-3-3 determina-
tion for NSA-abs. In addition, CSF samples from 49 patients
with pathologically confirmed CJD registered in the epide-
miologic surveillance center of Catalonia and the Neurologi-
cal Tissue Bank of the Biobank of Institut d’Investigacions
BiomèdiquesAugustPi i Sunyer (IDIBAPS)were tested forNSA-
abs. We examined the frequency of positive 14-3-3 test re-
sults in the CSF of 24 consecutive patients with severe anti-
NMDAR encephalitis (modified Rankin scale score, 4-5 [full
range of the scale, 0-6]) and 29with anti–leucine-rich glioma-
inactivated 1 (LGI1) encephalitis (modifiedRankin scale score
not specified in the clinical records, but all patients had vari-
able degrees of memory loss and confusion).
TheCSFsamplesused in thestudyaredeposited in thecol-
lection of biological samples named neuroinmunología regis-
tered in theBiobankof IDIBAPS.Written informedconsent for
the storageanduseof these samples for researchpurposeswas
obtained fromall patients. The studywasapprovedby theeth-
ics committee of the Hospital Clínic de Barcelona, Barcelona,
Spain.
14-3-3 Protein Assay and Immunologic Studies
The 14-3-3 proteinwas analyzed by immunoblot of the CSF as
previously described.13 Each sample was analyzed in dupli-
cate on different immunoblots. If the results were discor-
dant, the sample was analyzed a third time. All CSF samples
were tested forNSA-abs by immunohistochemistry on frozen
sections of nonperfused rat brain fixed in paraformaldehyde,
4%, solution using an avidin-biotin immunoperoxidase tech-
nique as previously described.14 In our laboratory, this tech-
nique shows a sensitivity similar to or higher than that of the
cell-based assays for all described NSA-abs with the excep-
tionofGlyR-abs. Positive caseswere further studiedusing im-
munofluorescence on cultures of fetal rat hippocampal neu-
ronsandhumanembryonickidney293cells expressingNMDA,
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid,
γ-aminobutyric acidB, metabotropic glutamate receptor 1
(mGluR1),mGluR5,GlyR, aquaporin4 (AQP4), LGI1, contactin-
associated protein-like 2 (CASPR2), and dipeptidyl-
peptidaselike protein-6 as previously described.14 The CSF of
definiteCJDcaseswasalso testedbycell-basedassays forGlyR,
NMDAR, LGI1, and CASPR2, regardless of the result of rat im-
munohistochemistry testing, to validate the possible occur-
rence of antibodies described in a few patients with CJDwith
a second assay.9-12
Results
During 2012, we received CSF samples of 346 patients to be
tested for the 14-3-3 protein. Forty patients (11.6%)had aposi-
tive 14-3-3 test result, 10 patients (2.9%) had positive staining
in rat brain immunohistochemistry, and 1 patient (0.3%) had
both. In 6 of the patients (1.7%) with positive rat immunohis-
tochemistry results, cell-based assays confirmed the pres-
ence of antibodies targeting the following antigens: CASPR2,
LGI1,NMDAR,AQP4,Tr (DNER[δ/notch-likeepidermalgrowth
factor–related receptor]), and 1 unidentified NSA, which was
confirmed on cultures of hippocampal neurons. The other 4
caseswithpositive rat immunohistochemistry findingsdidnot
reactwithNSAs inculturesofdissociatedrathippocampalneu-
rons, and the unknown intracellular antigens were no longer
studied.
The clinical features of the 6 patients with NSA-abs are
summarized (Table), and adetailed clinical description is pro-
vided (Supplement [eAppendix]). Briefly, 4 patients devel-
oped rapidly progressive cognitive decline, 3 of themwith as-
sociatedpsychiatric symptoms (CASPR2-abs,NMDAR-abs, and
unknown-abs). In theother2patients (LGI1-absandTr [DNER]-
abs), onlymotor abnormalitieswithout cognitivedeclinewere
reported.ThepatientwithLGI1-abspresentedwithmyoclonus-
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like movements involving the face and limbs (afterward de-
scribedas faciobrachialdystonic seizuresor tonic seizures),15,16
with alternate laterality. The patient with Tr (DNER)-abs de-
velopedasubacutecerebellar syndrome.Themediantimefrom
symptomonset to lumbar puncturewas 24days (range, 9-180
days). Analysis of the CSF revealed mild pleocytosis in 2 pa-
tients (Tr [DNER]-abs and unknown-abs), high protein con-
centration in2patients (NMDAR-absandAQP4-abs), andaposi-
tive 14-3-3 test result in 1 patient (Tr [DNER]-abs). Magnetic
resonance imaging features of limbic encephalitis were ob-
served in the patient with CASPR2-abs. Small cell lung carci-
nomawas detected in the patient with unknown-abs. Cancer
screening was performed in 4 other patients (CASPR2,
NMDAR,AQP4, andTr [DNER]); all resultswerenegative. Four
patients (CASPR2, LGI1, AQP4, and Tr [DNER]) received im-
munotherapy.Thepatientwithunknown-abswas treatedwith
chemotherapyandradiotherapy,andthepatientwithNMDAR-
abs underwent electroconvulsive therapy before the anti-
body was detected. Five patients improved and 1 patient
(Tr [DNER]-abs) stabilized.Thepatientwithunknown-abshad
full neurologic recovery but presented several months later
with relapsing cognitive decline; tumor recurrence was de-
tected.AlthoughCJDwas considered in thesepatientsby their
physicians in the differential diagnosis because of their rapid
clinical deterioration, noneof them fulfilled theWorldHealth
Organization, EuropeanConsortium, or University of Califor-
nia, SanFrancisco, diagnostic criteria for probable or possible
CJD.3,17,18
All 49 CSF samples of pathologically confirmed CJDwere
negative for NSA-abs. A nonspecific pattern of immunoreac-
tivity in paraformaldehyde-fixed rat brain was observed in 5
of the 49 samples, but additional studies using neuronal cul-
tureswerenegative, indicating that the immunoreactivitywas
not directed to surface antigens. Specific cell-based assays for
LGI1-abs, CASPR2-abs, GlyR-abs, and NMDAR-abs were also
negative in all 49 samples. None of the 24 patients with anti-
NMDAR encephalitis tested positive for 14-3-3 protein, and 1
of 29 patients (3.4%) with anti-LGI1 encephalitis was positive
for 14-3-3 protein.
Discussion
Our study indicates that a low, but clinically relevant, num-
ber of patients with suspected CJD have NSA-abs–associated
neurologic disorders that are potentially responsive to immu-
notherapy. Moreover, our patients with definite CJD did not
have CSF antibodies against NMDAR, GlyR, LGI1, or CASPR2
(the latter 2 includedwithin the term VGKC complex antibod-
ies). Conversely, none of the patients with anti-NMDAR en-
Table. Clinical Summary of PatientsWith Neuronal Antibodies Against Surface Antigens Initially Suspected to Have Creutzfeldt-Jakob Disease
Characteristic
Antibody Specificity
CASPR2 LGI1 NMDAR AQP4 Tr (DNER) Unidentified NSA
Sex/age at onset, y M/68 M/79 M/58 M/73 F/59 F/59
Instaurationa Insidious Acute Subacute Acute Acute Subacute








Gait instability Depression and
memory impairment
Cognitive decline Yes No Yes Yes No Yes
Myoclonus No No No No No Yes
Pyramidal signs Yes No No Yes Yes No
Cerebellar signs No No No No Yes No
Depression Yes No Yes No No Yes
Hallucinations No No Yes No No Yes
Psychosis Yes No No No No No
Seizures Yes Yesb Yes No No No
MRI results Medial temporal
lesions on FLAIR
sequences




CSF cell count Normal Normal Normal Normal 23 WBCs 14 WBCs
EEG results Diffuse slowing Normal Diffuse slowing FIRDA Normal Normal
Cancer No No No No No Yes (SCLC)










Improvement (final mRS) Yes (3) Yes (1) Yes (2) Yes (4) No (4) Yes (1)
Abbreviations: AQP4, aquaporin 4; CASPR2, contactin-associated protein-like 2;
CSF, cerebrospinal fluid; ECT, electroconvulsive therapy; EEG,
electroencephalogram; FIRDA, frontal intermittent rhythmic delta activity;
FLAIR, fluid-attenuated inversion recovery; LGI1, leucine-rich glioma-inactivated
1; MRI, magnetic resonance imaging; mRS; modified Rankin scale; NMDAR,
N-methyl-D-aspartate receptor; NSA, neuronal surface antigen; SCLC, small cell
lung carcinoma; Tr(DNER), δ/notch-like epidermal growth factor–related
receptor; WBCs, white blood cells.
a Time from first symptom to first medical evaluation: acute (<1 wk), subacute (1
wk-3 mo), and insidious (>3mo).
b Initially considered as myoclonus, retrospectively considered as faciobrachial
dystonic seizures.
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cephalitis and only 1 patient (3.4%) with anti-LGI1 encephali-
tis testedpositive for 14-3-3protein.Together, these results are
relevant for the initial assessmentofpatientswith rapidlypro-
gressive neurologic disorders suspected to be CJD.
A limitation of this study is that we were not able to ob-
taincomprehensive informationonallof thepatientswhowere
antibody negative. Therefore, there could have been addi-
tionalpatientswithpotentially treatable immunomediateddis-
orders that weremissed because the disorder was not associ-
atedwith antibodies or these antibodies were present only in
serum.However,webelieve the latter possibility is highlyun-
likely considering that all patients had CNS disorders.
The possible clinical overlap between prion diseases and
autoimmune encephalopathies has been addressed fromdif-
ferent perspectives byother investigators.19,20However, none
of the previous studies included a systematic analysis of both
NSA-abs and 14-3-3 protein in the CSF of patients with sus-
pected and pathologically confirmed CJD. The possibility of
misdiagnosingpotentially treatable diseases for CJDwas sug-
gestedbya study19 that showed that 6.4%ofpatientswith sus-
pected CJD had autopsy findings of potentially treatable dis-
eases,with immune-mediateddisorders themost frequent of
these.Furthermore, ina series20ofpatientswith suspectedau-
toimmune dementia and good response to immunotherapy,
almost9%of thedisordershadbeen initiallydiagnosedasCJD.
Patients with encephalitis associated with LGI1-abs may pre-
sentwithmyoclonus-likemovementsandothersymptomsthat
can be mistaken for CJD.21
In contrast to these studies on possible clinical overlap,
which were based on retrospective analyses of clinical and
pathologic information,weused anovel approachby system-
atically exploring thepresenceofNSA-abs in aprospective co-
hortof samples frompatients inwhomCJDwassuspected.Our
laboratory receives samples not only from reference centers
for thestudyofdementiabutalso fromgeneralhospitals,where
neurologists and geriatricians may be less aware of NSA-abs–
related CNS disorders. This ensures that our cohort is a good
representationof patientswith suspectedCJD inour environ-
ment.The identificationof 1.7%ofpatientswithsuspectedCJD
havingNSA-abs–relateddisorders isnear therangeof2%to10%
prevalence of immune-mediated CNS disorders reported in
studies22-24 of patients with rapidly progressive dementia.
The study of NSA-abs in CJD-suspected cases is impor-
tantbecause it identifiespotentially treatablepatients.Wemust
emphasize that noneof these patients fulfilled the current di-
agnostic criteria for probable or possible CJD; this diagnosis
was often considered by the referring physicians because of
the rapid development of neurologic symptoms with normal
or nonrevealing ancillary tests. Interestingly, 2 of the patients
did not have cognitive decline. Previous studies22-24 describ-
ing a clinical overlap between prion diseases and immune-
mediated disorders were focused primarily on rapidly pro-
gressivedementia.However, one should remember that ataxia
withoutcognitivedecline is a frequent initial symptominsome
molecular subtypes of sporadic CJD.3 In fact, it is not uncom-
monforpatientswith rapidlyprogressivecerebellar ataxia sus-
pected to be paraneoplastic to have CJD.8 Therefore, it is im-
portant toconsiderbothprionand immune-mediateddiseases
in the differential diagnosis of rapidly progressive neurologic
deficits,withorwithoutcognitive impairment, given thebroad
spectrum of symptoms of both disorders.
Using reported criteria14 that include immunohistochem-
istry testing on brain tissue optimized for cell surface or syn-
aptic proteins and recombinant cell-based assays, we did not
find antibodies directed against LGI1, CASPR2,NMDAR,GlyR,
or any other cell-surface antigen reported to date (excluding
dopamine receptors, whichwere not investigated) in the CSF
of 49 patients with definite CJD. These findings differ from
those of previous studies that included fewpatients, suggest-
ing that some patientswith CJDmay haveNMDAR-abs, GlyR-
abs, or VGKC complex–abs. The interpretation of those stud-
ies,however,has important limitations.First, apoordefinition
of the antigen was used.12 For example, the interpretation of
VGKC complex–abs without clarifying whether they are di-
rected against LGI1 or CASPR2 is complicated because VGKC
complex–abs that differ from LGI1 and CASPR2 have limited
syndrome specificity and are not reliable indicators of re-
sponse to immunotherapy.25,26 Second, the NMDAR-abs and
GlyR-abs were detected only in serum, casting doubts on the
potential pathogenic relevance.9,11 In all, these findings em-
phasize the need to also determine antibodies in CSF to avoid
potential pitfalls.
Overall, data from the present study and of previous re-
ports suggest that patients suspected to have CJD, particu-
larly those without supportive ancillary tests (typical mag-
netic resonance imagingor electroencephalographic findings)
shouldbe examined for thepresenceofNSA-abs.Detectionof
these antibodies indicates a potentially treatable disorder.
However, negative determination does not rule out the pos-
sibility of a potentially treatable immune-mediated disorder.
Patients in this series with definite CJD did not have antibod-
ies directed against NMDAR, GlyR, LGI1, or CASPR2 in their
CSF. Conversely, patients with anti-NMDAR encephalitis did
not have 14-3-3 protein in their CSF, although this test may
be positive in a small percentage of patients with anti-LGI1
encephalitis.
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